Prostate Specific Antigen (non-complexing fPSA)

Prostate Specific Antigen (non-complexing fPSA)

Catalog Number P5125 Download Specifications »
Purity ≥ 98% by SDS-PAGE  

General Product Information

Free PSA (fPSA) is isolated from human seminal fluid and is supplied as a liquid in 10mM Tris, 0.1% Sodium Azide, pH 8.0 ± 0.1. The non-complexing form is purified from material used to prepare the PSA-ACT Complex. The protein concentration for P0723 is determined by immunoassay. The protein concentration for other forms is determined by A280 using an extinction coefficient of 1.86 (Emg/ml = 1.86). Both of the complexed forms are prepared by in-vitro complex formation with the purified proteins. PSA-ACT complex is supplied as a liquid in 10mM Sodium Acetate, 150mM Sodium Chloride, 0.1% Sodium Azide, pH 5.6 ± 0.1. The protein concentration is determined by A280 using an extinction coefficient of 1.0 (Emg/ml = 1.0). PSA-A2M is supplied as a liquid in 20mM Sodium Phosphate, 150mM Sodium Chloride, 0.05% Sodium Azide, pH 7.4 ± 0.1. Protein is determined using the Bradford method (BSA standard).

Prostate Specific Antigen (PSA), a glycoprotein of the glandular kallikrein family, is a serine protease with chymotrypsin-like enzymatic activity. It has a molecular weight of approximately 33,000-34,000 Da and is found primarily in prostate tissue and seminal fluid. Serum levels of PSA are very low in healthy individuals (0 - 4 ng/ml), but are often elevated in malignant and benign prostatic disease. As such, immunoassays for serum levels of PSA have proven useful in the diagnosis and follow-up of prostate cancer.

PSA released into circulation is present as unbound, free PSA (fPSA) or bound to serum protease inhibitors, such as α1-antichymotrypsin (ACT) and α2-macroglobulin (A2M). Research indicates that immunoassays for serum levels of PSA alone cannot be relied on to distinguish prostate cancer from benign prostatic hyperplasia (BPH). Serum levels of PSA-ACT complex are reportedly higher in patients with prostate cancer than in those with BPH. As such, measuring the ratio of PSA-ACT to fPSA in patient samples is proving valuable in the differential diagnosis os prostate cancer. In addition, immunoassays for PSA-A2M serum levels may prove valuable in prostate cancer diagnosis, but further study is required.

See Also

  • Monoclonal and Polyclonal Antibodies for PSA.

 

Request Quote for Prostate Specific Antigen (non-complexing fPSA)

There are errors in your submission. Please check the form for highlighted fields.








Thank you for your product quote request.  One of our team members will contact you with a quote.

Copyright © 2010 Scripps Laboratories. All Rights Reserved.

6838 Flanders Drive, San Diego, CA 92121

Phone: (858) 546-5800

Fax: (858) 546-5812